General Information of Drug (ID: DMW9R1C)

Drug Name
AZD5305
Synonyms
AZD5305; Saruparib; 2589531-76-8; AZD-5305; 16MZ1V3RBT; 5-(4-((7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)-N-methylpicolinamide; saruparib [INN]; 2-Pyridinecarboxamide, 5-(4-((7-ethyl-5,6-dihydro-6-oxo-1,5-naphthyridin-3-yl)methyl)-1-piperazinyl)-N-methyl-; 2-Pyridinecarboxamide, 5-[4-[(7-ethyl-5,6-dihydro-6-oxo-1,5-naphthyridin-3-yl)methyl]-1-piperazinyl]-N-methyl-; UNII-16MZ1V3RBT; Azd 5305; CHEMBL5095220; SCHEMBL22912701; GTPL11526; AZD 5305 [WHO-DD]; AZD-5305 [WHO-DD]; EX-A5234; NSC834196; example 4 [WO2021013735]; NSC-834196; AC-37130; MS-26971; SY295016; HY-132167; CS-0163534; E80364; 5-[4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]-1-piperazinyl]-N-methylpicolinamide; 5-[4-[(7-ethyl-6-oxo-5H-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl]-N-methylpyridine-2-carboxamide; 5-{4-[(7-ethyl-5,6-dihydro-6-oxo-1,5-naphthyridin-3- yl)methyl]piperazin-1-yl}-N-methylpyridine-2- carboxamide
Indication
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Phase 2 [1]
Drug Type
Small molecule
Structure
3D MOL 2D MOL
Chemical Identifiers
Formula
C22H26N6O2
Canonical SMILES
CCC1=CC2=C(C=C(C=N2)CN3CCN(CC3)C4=CN=C(C=C4)C(=O)NC)NC1=O
InChI
InChI=1S/C22H26N6O2/c1-3-16-11-19-20(26-21(16)29)10-15(12-24-19)14-27-6-8-28(9-7-27)17-4-5-18(25-13-17)22(30)23-2/h4-5,10-13H,3,6-9,14H2,1-2H3,(H,23,30)(H,26,29)
InChIKey
WQAVGRAETZEADU-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
155586901
TTD ID
D0YTM9

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Poly [ADP-ribose] polymerase 1 (PARP1) TTVDSZ0 PARP1_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Prostate cancer
ICD Disease Classification 2C82.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Poly [ADP-ribose] polymerase 1 (PARP1) DTT PARP1 5.01E-05 1.02 2.68
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05367440) A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA). U.S.National Institutes of Health.
2 Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper. Clin Cancer Res. 2022 Nov 1;28(21):4724-4736.